Myriad Genetics (NASDAQ:MYGN) had a weak trading session and its shares were last down at $30.79, down -0.16% or -0.52 points. The trading data also revealed that the total net flow stood at $0.82 million as the shares had $2.42 million in upticks but lost $1.6 million in downticks. The up/down ratio was 1.51. This data is particularly important for the traders and speculators alike as it could also be used to gauge the strength of the momentum in the shares. During the past week, the shares have seen a change of -9.36% in the shares.The block trade data suggests an inflow of $0.72 million in upticks and an outflow of $0 million in downticks. The up/down ratio for the block stood at 0. The net money flow for this transaction was recorded at $0.72.
Currently the company Insiders own 5.8% of Myriad Genetics shares according to the proxy statements. On the companys insider trading activities,The officer (Exec. VP International Ops) of Myriad Genetics Inc, King Gary A. sold 15,000 shares at $39.03 on April 6, 2016. The Insider selling transaction had a total value worth of $585,450. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Myriad Genetics (NASDAQ:MYGN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.37 points or 1.2% at $30.58 with 1,725,591 shares getting traded. Post opening the session at $31.04, the shares hit an intraday low of $30.57 and an intraday high of $31.13 and the price was in this range throughout the day. The company has a market cap of $2,150 million and the number of outstanding shares have been calculated to be 70,298,970 shares. The 52-week high of Myriad Genetics (NASDAQ:MYGN) is $46.24 and the 52-week low is $30.3.
Many analysts have stated their opinion on the company shares. Avondale Partners maintains their rating on the shares of Myriad Genetics (NASDAQ:MYGN). The current rating of the shares is Market Outperform. Equity Analysts at the Firm lowers the price target to $47 per share from $50 per share. The rating by the firm was issued on May 4, 2016.
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing, or assess a patients risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.